<DOC>
	<DOCNO>NCT00190983</DOCNO>
	<brief_summary>This phase II trial study antitumor activity single agent pemetrexed 900mg/m2 IV 10 minute patient recurrent cervical cancer .</brief_summary>
	<brief_title>A Trial Patients With Advanced/Recurrent Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Recurrent squamous nonsquamous cell carcinoma cervix document disease progression Measurable disease Gynecologic Oncology Group ( GOG ) performance status 02 Patients must receive one prior systemic chemotherapy persistent recurrent disease Patients mild moderate renal insufficiency avoid take nonsteroidal antiinflammatory drug ( NSAIDs_ short elimination halflives period 2 day , day , 2 day follow administration pemetrexed . All patient take NSAIDs longer halflives , interrupt dose least 5 day , day , 2 day follow pemetrexed administration . Folic Acid ( 3501000 ug ) must give daily begin approximately 57 day prior first pemetrexed continue daily 3 week last dose study therapy . Vitamin B12 ( 1000 ug ) administer intramuscular injection approximately 1 2 week prior first dose pemetrexed repeat approximately every 9 week 3 week last dose study therapy Prior Pemetrexed Patients receive radiation 25 % marrow bear area Any evidence malignancy within last 5 year , exception nonmelanoma skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>